Noida Chronicle

Higher-Risk Chronic Myelomonocytic Leukemia Treatment Market, Pipeline, Epidemiology, Drugs, and Companies by DelveInsight | Argenx, Novartis, Kura Oncology, Sensei Biotherapeutics, Takeda and Ma

 Breaking News
  • No posts were found

Higher-Risk Chronic Myelomonocytic Leukemia Treatment Market, Pipeline, Epidemiology, Drugs, and Companies by DelveInsight | Argenx, Novartis, Kura Oncology, Sensei Biotherapeutics, Takeda and Ma

May 09
19:20 2022
Higher-Risk Chronic Myelomonocytic Leukemia Treatment Market, Pipeline, Epidemiology, Drugs, and Companies by DelveInsight | Argenx, Novartis, Kura Oncology, Sensei Biotherapeutics, Takeda and Ma
Higher-Risk Chronic Myelomonocytic Leukemia Treatment Market

DelveInsight’s “Higher-Risk Chronic Myelomonocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Higher-Risk Chronic Myelomonocytic Leukemia, historical and forecasted epidemiology as well as the Higher-Risk Chronic Myelomonocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of Higher Risk Chronic Myelomonocytic Leukemia Market are:

  • CMML affects approximately 3 out of 100,000 individuals in the United States each year.
  • The risk of CMML increases with age. This disease is rare in those younger than 40, with most cases found in people 60 and older.
  • Median survival of patients with CMML is reported to be approximately 12 to 40 months.
  • Through various secondary studies it can be concluded that overall HR-CMML affects more males than females.
  • The disease incidence rate ranges between 3.5 and 4.1/1 000 000 per year in the United States and in Europe.
  • On an average, patients with CMML demonstrate ~10-15 mutations per kilobase of coding DNA regions, similar to patients with acute myeloid leukemia (AML), but several folds lower than other malignancies such as melanoma and lung cancer.

 

 

Some of Higher Risk Chronic Myelomonocytic Leukemia companies are:

  • Pharmion Corporation
  • Otsuka America Pharmaceutical
  • Argenx
  • Novartis
  • Kura Oncology
  • Sensei Biotherapeutics
  • Takeda
  • Humanigen
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/higher-risk-chronic-myelomonocytic-leukemia-market

 

Chronic Myelomonocytic Leukemia (CMML) is a rare, clonal hematopoietic stem cell disorder characterized by the presence of sustained (>3 months) peripheral blood (PB) monocytosis (≥1 × 109/L; monocytes ≥10% of white blood cell count) along with dysplastic features in the bone marrow (BM). CMML has some similarities with a condition called myelodysplastic syndrome (MDS) and some resemblance to a group of conditions called myeloproliferative neoplasms (MPN). It is classified as being a mixture of these two conditions.

CMML shares clinical and biological features with MDS, including cytopenia and bone marrow failure, risk of progression to AML, and overlapping, recurring, cytogenetic abnormalities.

CMML can be further subdivided into two categories depending on the number of blasts found in the peripheral blood and bone marrow, CMML-1 with less than 5% blasts in peripheral blood and less than 10% in bone marrow, and CMML-2 with 5 to 19% blasts in peripheral blood and/or 10 and 19% in the bone marrow.

 

Some of Higher Risk Chronic Myelomonocytic Leukemia therapies are:

  • Vidaza
  • Dacogen
  • Cusatuzumab
  • MBG453
  • Tipifarnib
  • SNS-301
  • Pevonedistat
  • Lenzilumab
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/higher-risk-chronic-myelomonocytic-leukemia-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Higher-Risk Chronic Myelomonocytic Leukemia

3. Competitive Intelligence Analysis for Higher-Risk Chronic Myelomonocytic Leukemia

4. Higher-Risk Chronic Myelomonocytic Leukemia : Market Overview at a Glance

5. Higher-Risk Chronic Myelomonocytic Leukemia : Disease Background and Overview

6. Patient Journey

7. Higher-Risk Chronic Myelomonocytic Leukemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Higher-Risk Chronic Myelomonocytic Leukemia Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report